nach oben

Erschienen in:

18.09.2017 | Hypophysitis | zertifizierte fortbildung

Therapie mit Immuncheckpointinhibitoren

Management immunvermittelter Nebenwirkungen

verfasst von: Melanie Janning, Prof. Dr. Dr. Sonja Loges

Erschienen in: InFo Hämatologie + Onkologie | Sonderheft 1/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Therapie mit Immuncheckpointinhibitoren stellt Hämatologen und Onkologen vor neue Herausforderungen — auch, was die Nebenwirkungen betrifft. Das frühe Erkennen und Behandeln der Toxizitäten kann helfen, längerfristige Therapiepausen oder -abbrüche zu verhindern.

Eigentler TK et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18.PubMedCrossRef

Borghaei H et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39.PubMedCrossRef

Motzer RJ et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803–13.PubMedCrossRef

June CH et al. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med. 2017;23(5):540–7.PubMedCrossRef

Haanen J et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–iv42.PubMedCrossRef

Oncology ASCO. Guidelines Planned on Management of Immunotherapy Side Effects: ASCO and NCCN to Collaborate on Development. 16.02.2017 2017. http://www.asco.org/advocacy-policy/asco-in-action/guidelines-planned-management-immunotherapy-side-effects-asco-and (abgerufen am 24.08.2017).

Johnson DB et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016; 375(18):1749–55.PubMedPubMedCentralCrossRef

Naidoo J et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017;35(7):709–17.PubMedCrossRef

Champiat S et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–74.PubMedCrossRef

10.

Xiao X, Chang C. Diagnosis and classification of drug-induced autoimmunity (DIA). J Autoimmun. 2014;48-49:66–72.PubMedCrossRef

11.

Weber JS et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2017;35(7):785–92.CrossRef

12.

Naidoo J et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–91.PubMed

13.

Robert C et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–32.PubMedCrossRef

14.

Weber JS et al. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–7.PubMedCrossRef

15.

Ryder M et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-related cancer 2014;21(2):371–81.PubMedPubMedCentralCrossRef

16.

Garon EB et al. Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. N Engl J Med. 2015;372(21):2018–28.PubMedCrossRef

17.

Peters S et al. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017;35(24):2781–9.PubMedCrossRef

18.

Larkin J et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34.CrossRef

19.

Postow MA et al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Engl J Med. 2015;372(21):2006–17.PubMedCrossRef

20.

Wolchok JD et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64.PubMedCrossRef

21.

Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. The N Engl. J Med. 2010;363(8):711–23.PubMedCrossRef

22.

Eggermont AM et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016;375(19):1845–55.PubMedCrossRef

23.

Hua C et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA dermatology. 2016;152(1):45–51.PubMedCrossRef

24.

Reck M et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823–33.PubMedCrossRef

25.

Osorio JC et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583–9.PubMed

26.

Gonzalez-Rodriguez E et al. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist. 2016;21(7):804–16.PubMedPubMedCentralCrossRef

27.

Iwama S et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45.PubMedCrossRef

28.

Mellati M et al. Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes. Diabetes care. 2015;38(9): e137–8.PubMedCrossRef

29.

Gupta A et al. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42(4):406–17.PubMedCrossRef

30.

Marthey L et al. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(4):395–401.PubMedPubMedCentralCrossRef

31.

Berman D et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11.PubMedPubMedCentral

32.

Bergqvist V et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66(5):581–92.PubMedPubMedCentralCrossRef

33.

Chaput N et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368–79.PubMedCrossRef

34.

Maker AV et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006;29(4):455–63.PubMedPubMedCentralCrossRef

35.

Gonzalez RS et al. PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‚immunomodulatory gastroenterocolitis‘. Histopathology. 2017;70(4):558–67.PubMedCrossRef

36.

Collins M et al. Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade. J Crohns Colitis. 2017;11(suppl1):S237.CrossRef

37.

Nishino M et al. Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med. 2015;373(3):288–90.PubMedPubMedCentralCrossRef

38.

Santini FC et al. Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol. 2017;35(15_suppl):Abstr 9012.

Titel: Therapie mit Immuncheckpointinhibitoren
Management immunvermittelter Nebenwirkungen
verfasst von: Melanie Janning
Prof. Dr. Dr. Sonja Loges
Publikationsdatum: 18.09.2017
Verlag: Springer Medizin
Schlagwörter: Hypophysitis
Checkpoint-Inhibitoren
Checkpoint-Inhibitoren
Prednisolon
Erschienen in: InFo Hämatologie + Onkologie / Ausgabe Sonderheft 1/2017
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI: https://doi.org/10.1007/s15004-017-5562-6

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2017

Immuntherapie von Nieren-, Prostatakarzinom & Co.

Immuntherapie beim Hodgkin-Lymphom

Langzeitdaten zur Kombination von PD-1- und CTLA-4-Blockade

Immuntherapie thorakaler Tumoren

PD-1-Blockade zeigt Erfolge

Wie lassen sich Responder identifizieren?